Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Adipose-derived regenerative cell therapy mitigates sepsis-induced cardiomyopathy through the induction of cardiac reparative lymphangiogenesis.

Luo H., Shimizu Y., Chen X., Liu T., Che Y., Matsuoka Y.

Animal Study on Cardiovascular Disease, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Res Ther (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
42002800
PMCID
PMC13224632
DOI
10.1186/s13287-026-05023-3
Citations
1

Abstract (original English)

Background and purpose Sepsis-induced cardiomyopathy (SICM) represents a critical unmet clinical challenge globally and is highlighted by the paucity of effective therapeutic interventions. Despite its clinical importance, the exacerbating factors and intricate underlying mechanisms remain largely unknown. Emerging evidence has highlighted the pivotal role of the cardiac lymphatic vasculature in cardiac homeostasis and repair, prompting investigations into its contributions during pathological states. In this study, we delineated the dynamics and functional significance of cardiac lymphatic vessels in SICM pathogenesis, and evaluated the therapeutic efficacy of targeted lymphangiogenesis as a novel strategy to improve poor prognosis. Methods and results Using a lipopolysaccharide (LPS)-induced SICM mouse model, the evolution of cardiac lymphatic kinetics and observed reparative lymphangiogenesis was assessed in SICM. In addition, pharmacological inhibition of reparative lymphangiogenesis further exacerbated mortality rates in this model, thus highlighting its protective contributions. Adipose-derived regenerative cells (ADRCs) robustly enhance lymphangiogenesis in cardiac tissues during SICM. In vitro assays with lymphatic endothelial cells (LECs) confirmed that this lymphangiogenic potency is mediated, at least in part, by vascular endothelial growth factor-C (VEGF-C) secreted

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsLymphangiogenesisCardiomyopathiesSepsisMiceVascular Endothelial Growth Factor CAdipose TissueDisease Models, AnimalEndothelial CellsMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research